Novel insights into mesothelioma biology and implications for therapy, Nat Rev Cancer, vol.17, pp.475-488, 2017. ,
, , 2017.
, Infectious Optimism following the 10th International Oncolytic Virus Meeting, Mol Ther Oncolytics, vol.7, pp.12-16
Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery, Front Oncol, p.96, 2017. ,
Cytokine gene therapy or infusion as treatment for solid human cancer, J Immunother, vol.21, pp.211-217, 1998. ,
, , 2000.
, Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation, Cancer Gene Ther, vol.7, pp.663-670
Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma, Hum Gene Ther, vol.19, pp.774-782, 2008. ,
Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene, Clin Cancer Res, vol.15, pp.3791-3801, 2009. ,
An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma, Surgery, vol.154, pp.486-495, 2013. ,
Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis, Clin Cancer Res, vol.24, pp.4388-4398, 2018. ,
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism, Mol Ther Oncolytics, vol.14, pp.1-14, 2019. ,
Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies, Oncogene, vol.34, pp.2011-2021, 2015. ,
Sensitivity of pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response, Oncotarget Dec, vol.29, pp.44892-44904, 2015.,
URL : https://hal.archives-ouvertes.fr/inserm-01285131
, , 2009.
, Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components, J Virol, vol.83, pp.1563-1571
CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy, Oncoimmunology, vol.5, p.1091554, 2016. ,
Intratumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines, Oncoimmunology, vol.7, p.1395997, 2018. ,
, , 2014.
, Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma, Annals of surgical oncology, vol.21, pp.2259-2266
Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-alpha Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy, Cancer Res, vol.77, pp.4146-4157, 2017. ,
Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes, OncoTargets and therapy, vol.10, pp.2389-2401, 2017. ,